Breaks Categories: News

TuesdayNov 24, 2020 1:49 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Stock2Me Podcast

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in InvestorBrandNetwork’s (“IBN”) latest episode of its Stock2Me Podcast. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are revolutionizing business practices within their respective markets. AZRX president and CEO James Sapirstein joins IBN’s Stuart Smith in the latest episode to discuss how AzurRx is working to redefine the standard of care for patients living with cystic fibrosis and chronic pancreatitis. “AzurRx Bio has been around for five years. … Our main product, MS1819, is being studied in…

Continue Reading

TuesdayNov 24, 2020 1:22 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Brain Cancer Drug During Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. During the broadcast, CNS Pharmaceuticals CEO John Climaco explains that the company has recently submitted an investigational new drug (“IND) application to the U.S. Food & Drug Administration (“FDA”) for its brain cancer drug, Berubicin. Climaco also discusses CNSP’s intent to begin Phase 2 trials of the drug during Q1 2021. The Phase 2 trial is designed to analyze the efficacy of Berubicin in treating patients with Glioblastoma…

Continue Reading

TuesdayNov 24, 2020 1:00 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Diamond Equity Research Emerging Growth Invitational

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on Dec. 1, 2020. According to the update, Genprex’s executive vice president and COO, Michael Redman, will virtually deliver a company overview to investors followed by a guided question and answer session. Redman’s presentation is scheduled to begin at 11:30 a.m. ET on Dec. 1. Interested parties may visit https://ibn.fm/buX50 to register for the webinar. A live audio webcast and archive of the conference…

Continue Reading

TuesdayNov 24, 2020 10:45 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Outlines Investor Initiatives, Announces Conference Presentation

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, announced its upcoming investor awareness initiatives today. In addition, the company will be conducting a presentation today at the Future of Food Investment Conference; one-on-one investor meetings are also being scheduled for next week. According to the announcement, MustGrow’s key programs and catalysts include testing of its biopesticide, which is formulated to stop Fusarium wilt TR4, a disease pathogen ravaging the $25 billion global banana industry; filing of key patents and progress on proof-of-concept data related to a biological…

Continue Reading

MondayNov 23, 2020 12:35 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Secures Additional Patents, Significantly Strengthening IP Portfolio

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the continued expansion of its IP portfolio. According to the update, the company, on Nov. 20, 2020, received notice from the USPTO that it will publish application 62/722,263 “Method of treating frozen shoulder using an il-33/TNF bispecific antibody.” The patent application is a continuation of US Patent No. 10,500,2730 and, once granted, it will be assigned patent number US-2020-0338193-A 1. 180 Life Sciences also…

Continue Reading

FridayNov 20, 2020 11:02 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Simply Wall St Article

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in a recent Simply Wall St article. The piece, titled “Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?,” explores the rate of the company’s annual negative free cash flow (“cash burn”) and whether it should be concerning to shareholders. The article reads, “Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought AzurRx BioPharma's cash burn reduction was relatively promising. Even though we don't think…

Continue Reading

ThursdayNov 19, 2020 11:53 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Presents Promising Dario DTx Study Results

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, presented results from a new clinical study of 940 members at the 20th Annual Diabetes Technology Society Meeting (“DTS”). According to the update, the results showed a marked reduction in the percentage of high blood glucose readings and in the average blood glucose readings in adults over the age of 65 years using Dario's digital therapeutics platform (“Dario DTx”). “We believe that Dario's DTx platform plays a role in driving behavioral modification and enhances adherence to diabetes and other chronic condition management in older adults,” said Yifat Hershcovitz, Ph.D.,…

Continue Reading

ThursdayNov 19, 2020 10:42 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Joint Sponsor 2020 SNO Virtual Meeting

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, will be joint sponsoring the 2020 Society of NeuroOncology (“SNO”) Virtual Meeting. CNS will be sharing sponsorship with WPD Pharmaceuticals. The virtual event is slated for Nov. 19–21, 2020. The joint sponsorship includes a booth in the virtual exhibit hall and is categorized as a Supporter level. In addition, one of the panel discussions will feature a member of CNS’s Science Advisory Board; Dr. Patrick Wen will be part of the panel discussing clinical…

Continue Reading

WednesdayNov 18, 2020 10:37 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Places MiQLab(TM) System in Penn Vet Microbiology Laboratory

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has placed a MiQLab(TM) system into the clinical microbiology laboratory at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet) as part of its Early Access Program. Penn Vet provides animal patient testing at the Ryan Veterinary Hospital and for patients of practices across the United States, processing thousands of samples each year. “We are very excited to be placing our first completed commercial MiQLab system in the Penn Vet microbiology laboratory for their evaluation,” said Dr.…

Continue Reading

WednesdayNov 18, 2020 10:07 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in A.G.P. Healthcare Symposium

CNS Pharmaceuticals (NASDAQ: CNSP) management will be participating in A.G.P.’s upcoming Virtual Healthcare Symposium. The symposium is scheduled for Nov. 19, 2020. Leaders of CNSP, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, will be part of the event, which includes one-on-one virtual investor meetings. Potential investors who may want to attend the conference should contact an A.G.P. representative. CNS plans to start a Phase 2 clinical trial of its lead drug candidate Berubicin, which is designed to treat glioblastoma multiforme (“GBM”), an aggressive and incurable form of…

Continue Reading